Abstract
In contrast to airway diseases like chronic obstructive pulmonary disease or asthma, and rare diseases such as cystic fibrosis, there has been little research and few clinical trials in bronchiectasis. Guidelines are primarily based on expert opinion and treatment is challenging because of the heterogeneous nature of the disease. In an effort to address decades of underinvestment in bronchiectasis research, education and clinical care, the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was established in 2012 as a collaborative pan-European network to bring together bronchiectasis researchers. The European Respiratory Society officially funded EMBARC in 2013 as a Clinical Research Collaboration, providing support and infrastructure to allow the project to grow. EMBARC has now established an international bronchiectasis registry that is active in more than 30 countries both within and outside Europe. Beyond the registry, the network participates in designing and facilitating clinical trials, has set international research priorities, promotes education and has participated in producing the first international bronchiectasis guidelines. This manuscript article the development, structure and achievements of EMBARC from 2012 to 2017.
| Original language | English |
|---|---|
| Pages (from-to) | 180-192 |
| Number of pages | 13 |
| Journal | Breathe |
| Volume | 13 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Sep 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
The European multicentre bronchiectasis audit and research collaboration (EMBARC) : Experiences from a successful ERS clinical research collaboration. / Chalmers, James D.; Crichton, Megan; Goeminne, Pieter C.; Loebinger, Michael R.; Haworth, Charles; Almagro, Marta; Vendrell, Montse; De Soyza, Anthony; Dhar, Raja; Morgan, Lucy; Blasi, Francesco; Aliberti, Stefano; Boyd, Jeanette; Polverino, Eva; EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group.
In: Breathe, Vol. 13, No. 3, 01.09.2017, p. 180-192.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The European multicentre bronchiectasis audit and research collaboration (EMBARC)
T2 - Experiences from a successful ERS clinical research collaboration
AU - Chalmers, James D.
AU - Crichton, Megan
AU - Goeminne, Pieter C.
AU - Loebinger, Michael R.
AU - Haworth, Charles
AU - Almagro, Marta
AU - Vendrell, Montse
AU - De Soyza, Anthony
AU - Dhar, Raja
AU - Morgan, Lucy
AU - Blasi, Francesco
AU - Aliberti, Stefano
AU - Boyd, Jeanette
AU - Polverino, Eva
AU - EMBARC, the European Lung Foundation (ELF) and the EMBARC/ELF patient advisory group
PY - 2017/9/1
Y1 - 2017/9/1
N2 - In contrast to airway diseases like chronic obstructive pulmonary disease or asthma, and rare diseases such as cystic fibrosis, there has been little research and few clinical trials in bronchiectasis. Guidelines are primarily based on expert opinion and treatment is challenging because of the heterogeneous nature of the disease. In an effort to address decades of underinvestment in bronchiectasis research, education and clinical care, the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was established in 2012 as a collaborative pan-European network to bring together bronchiectasis researchers. The European Respiratory Society officially funded EMBARC in 2013 as a Clinical Research Collaboration, providing support and infrastructure to allow the project to grow. EMBARC has now established an international bronchiectasis registry that is active in more than 30 countries both within and outside Europe. Beyond the registry, the network participates in designing and facilitating clinical trials, has set international research priorities, promotes education and has participated in producing the first international bronchiectasis guidelines. This manuscript article the development, structure and achievements of EMBARC from 2012 to 2017.
AB - In contrast to airway diseases like chronic obstructive pulmonary disease or asthma, and rare diseases such as cystic fibrosis, there has been little research and few clinical trials in bronchiectasis. Guidelines are primarily based on expert opinion and treatment is challenging because of the heterogeneous nature of the disease. In an effort to address decades of underinvestment in bronchiectasis research, education and clinical care, the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) was established in 2012 as a collaborative pan-European network to bring together bronchiectasis researchers. The European Respiratory Society officially funded EMBARC in 2013 as a Clinical Research Collaboration, providing support and infrastructure to allow the project to grow. EMBARC has now established an international bronchiectasis registry that is active in more than 30 countries both within and outside Europe. Beyond the registry, the network participates in designing and facilitating clinical trials, has set international research priorities, promotes education and has participated in producing the first international bronchiectasis guidelines. This manuscript article the development, structure and achievements of EMBARC from 2012 to 2017.
UR - http://www.scopus.com/inward/record.url?scp=85035811855&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85035811855&partnerID=8YFLogxK
U2 - 10.1183/20734735.005117
DO - 10.1183/20734735.005117
M3 - Article
VL - 13
SP - 180
EP - 192
JO - Breathe
JF - Breathe
SN - 1810-6838
IS - 3
ER -